MCD
MCID: KPS004
MIFTS: 76

Kaposi Sarcoma (MCD)

Categories: Blood diseases, Cancer diseases, Cardiovascular diseases, Fetal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Kaposi Sarcoma

MalaCards integrated aliases for Kaposi Sarcoma:

Name: Kaposi Sarcoma 57 12 76 53 59 37 55 43 15 73
Kaposi's Sarcoma 12 53 29 15
Kaposi Sarcoma, Susceptibility to 57 13 6
Angiofollicular Ganglionic Hyperplasia 59 73
Kaposi's Sarcoma of Soft Tissue 12 73
Kaposi's Sarcoma of Palate 12 73
Kaposi's Sarcoma of Lung 12 73
Multiple Idiopathic Pigmented Hemangiosarcoma, Susceptibility to 57
Multiple Idiopathic Pigmented Hemangiosarcoma 57
Kaposi's Sarcoma of Central Nervous System 12
Kaposi's Sarcoma of Gastrointestinal Sites 12
Multicentric Giant Lymph Node Hyperplasia 59
African Lymphadenopathic Kaposi's Sarcoma 12
Central Nervous System Kaposi's Sarcoma 12
Kaposi's Sarcoma-Associated Herpesvirus 12
Kaposi's Sarcoma of the Gallbladder 12
Sarcoma, Kaposi, Susceptibility to 40
Angiofollicular Lymph Hyperplasia 59
Lymphadenopathic Kaposi's Sarcoma 12
Multi-Centric Castleman's Disease 73
Kaposi's Sarcoma of Soft Tissues 12
Kaposi's Sarcoma of the Prostate 12
Kaposi's Sarcoma of Conjunctiva 12
Kaposi's Sarcoma of Lymph Nodes 12
Non Aids Related Kaposi Sarcoma 53
Non-Aids-Related Kaposi Sarcoma 73
Multicentric Castleman Disease 59
Conjunctival Kaposi's Sarcoma 12
Kaposi's Sarcoma of Esophagus 12
Gallbladder Kaposi's Sarcoma 12
Soft Tissue Kaposi's Sarcoma 12
Mediterranean Kaposi Sarcoma 53
Esophageal Kaposi's Sarcoma 12
Intestinal Kaposi's Sarcoma 12
Kaposi's Sarcoma of the Cns 12
Lymph Node Kaposi's Sarcoma 12
Cutaneous Kaposi's Sarcoma 12
Kaposi's Sarcoma of Cornea 12
Pulmonary Kaposi's Sarcoma 12
Kaposi Sarcoma Herpesvirus 53
Kaposi's Sarcoma of Heart 12
Kaposi's Sarcoma of Penis 12
Prostate Kaposi's Sarcoma 12
Angiolymphoid Hyperplasia 73
Cardiac Kaposi's Sarcoma 12
Corneal Kaposi's Sarcoma 12
Gastric Kaposi's Sarcoma 12
Kaposi's Sarcoma of Anus 12
Kaposi's Sarcoma of Skin 12
Palate Kaposi's Sarcoma 12
Kaposi's Sarcoma, Lung 12
Kaposi's Sarcoma, Skin 12
Penis Kaposi's Sarcoma 12
Anal Kaposi's Sarcoma 12
Human Herpesvirus 8 53
Castleman Disease 59
Sarcoma, Kaposi 44
Hhv8 53
Kshv 53
Mcd 59

Characteristics:

Orphanet epidemiological data:

59
kaposi sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult;
castleman disease
Inheritance: Not applicable; Age of onset: All ages;

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
kaposi sarcoma:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Kaposi Sarcoma

NIH Rare Diseases : 53 Kaposi sarcoma (KS) is a cancer that develops from the cells that line lymph or blood vessels. It usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but tumors can also develop in other parts of the body (including the lymph nodes, lungs, or digestive tract). The abnormal cells of Kaposi sarcoma cause purplish, reddish blue, or dark brown/black skin lesions (macules, nodules, plaques) on the legs and the face. These lesions may look bad, but they usually cause no symptoms. However, when the lesions are in the lungs, liver, or digestive tract, they may cause serious problems like gastrointestinal bleeding or trouble breathing. Kaposi sarcoma is caused by infection with a virus called the Kaposi sarcoma associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8). Kaposi sarcoma is classified into four types based upon the different populations in which it develops: classic (which presents in middle or old age), endemic (described in sub-Saharan indigenous Africans), iatrogenic (associated with immunosuppressive drug therapy) and AIDS-associated (epidemic KS). Options for treatment may include local therapy, radiation therapy, chemotherapy and biologic therapy (immunotherapy). The main aim is to restore immunity.

MalaCards based summary : Kaposi Sarcoma, also known as kaposi's sarcoma, is related to sarcoma and acquired immunodeficiency syndrome, and has symptoms including fever, pruritus and exanthema. An important gene associated with Kaposi Sarcoma is IL6 (Interleukin 6), and among its related pathways/superpathways are Kaposi sarcoma-associated herpesvirus infection and Viral carcinogenesis. The drugs Taxol and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and lung, and related phenotypes are fever and fatigue

Disease Ontology : 12 A connective tissue cancer that derives from lymphatic endothelium, and derives from spindle cells, results in_formation_of vascular channels that fill with blood cells, has material basis in Human herpesvirus 8 (HHV8).

OMIM : 57 Kaposi sarcoma (KS) is an invasive angioproliferative inflammatory condition that occurs commonly in men infected with human immunodeficiency virus (HIV; see 609423). In the early stages of KS, lesions appear reactive and are stimulated to grow by the actions of inflammatory cytokines and growth factors. In the late stages of KS, a malignant phenotype that appears to be monoclonal can develop. Infection with human herpesvirus-8 (HHV-8), also known as KS-associated herpesvirus (KSHV), is necessary but not sufficient for KS development. Coinfection with HIV markedly increases the likelihood of KS development, and additional environmental, hormonal, and genetic cofactors likely contribute to its pathogenesis (summary by Foster et al., 2000). Suthaus et al. (2012) noted that HHV-8 is the etiologic agent not only of KS, but also of primary effusion lymphoma and plasma cell-type multicentric Castleman disease (MCD). (148000)

MedlinePlus : 43 Kaposi sarcoma (KS) is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat, in lymph nodes, or in other organs. These patches, or lesions, are usually red or purple. They are made of cancer cells, blood vessels, and blood cells. KS is caused by infection with human herpesvirus-8 (HHV-8). Most people infected with HHV-8 don't get KS. It usually happens in People with weak immune systems, due to HIV/AIDS, drugs taken after an organ transplant, or another disease Older men of Jewish or Mediterranean descent Young men in Africa The skin lesions may not cause symptoms. But they can spread to other parts of the body, especially in people with HIV/AIDS. If they spread to the digestive tract or lungs, they can cause bleeding. Lesions on the lungs can also make it hard to breathe. Treatment depends on where the lesions are and how bad they are. Options include radiation therapy, surgery, chemotherapy, and biologic therapy. People with HIV/AIDS also take HIV/AIDS Medicines. NIH: National Cancer Institute

Wikipedia : 76 Kaposi''s sarcoma (KS) is a type of cancer that can form masses in the skin, lymph nodes, or other... more...

Related Diseases for Kaposi Sarcoma

Diseases related to Kaposi Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 381)
# Related Disease Score Top Affiliating Genes
1 sarcoma 31.8 TP53 PDGFB KDR IL6ST IL6 ICAM1
2 acquired immunodeficiency syndrome 31.0 TP53 IL6 IFNA2 IFNA1
3 lymphangioma 30.8 VEGFA KDR IFNA2
4 viral infectious disease 30.5 IRF7 IL6 IFNB1 IFNA2 IFNA1
5 myeloma, multiple 30.3 VEGFA TP53 IL6 IFNA1 FGF2
6 rheumatoid arthritis 30.3 VEGFA IL6ST IL6 ICAM1 CXCL1
7 pericardial effusion 30.2 VEGFA IL6 FGF2
8 relapsing-remitting multiple sclerosis 30.0 IFNB1 IFNA1 ICAM1
9 retinal vascular disease 30.0 VEGFA KDR ICAM1
10 hepatitis c 29.9 IRF7 IFNB1 IFNA2 IFNA1
11 renal cell carcinoma, nonpapillary 29.8 VEGFA KDR IFNA2 IFNA1 FGF2
12 hepatocellular carcinoma 29.8 VEGFA TP53 KDR IL6 IFNA1 ICAM1
13 endemic kaposi sarcoma 12.4
14 colon kaposi sarcoma 12.3
15 pediatric castleman disease 12.2
16 immunodeficiency 16 12.1
17 human herpesvirus 8 12.1
18 malonyl-coa decarboxylase deficiency 12.0
19 macular dystrophy, corneal 11.9
20 multiple carboxylase deficiency 11.9
21 metaphyseal chondrodysplasia, schmid type 11.8
22 holocarboxylase synthetase deficiency 11.8
23 biotinidase deficiency 11.7
24 focal segmental glomerulosclerosis 11.5
25 lipoid nephrosis 11.5
26 littoral cell angioma of the spleen 11.2
27 rectum kaposi's sarcoma 11.2
28 c1q nephropathy 11.1
29 corneal dystrophy, meesmann 11.0
30 metaphyseal dysplasia, spahr type 11.0
31 cortical malformations, occipital 11.0
32 microlissencephaly 11.0
33 spindle cell sarcoma 10.6
34 lymphoma 10.6
35 castleman disease 10.5
36 multicentric castleman disease 10.5
37 primary effusion lymphoma 10.4
38 lymphoma, hodgkin, classic 10.3
39 human immunodeficiency virus infectious disease 10.3
40 macular retinal edema 10.3 VEGFA IL6 ICAM1
41 lymphoma, non-hodgkin, familial 10.3
42 lymphomatoid granulomatosis 10.3 IFNA2 IFNA1
43 arteriovenous malformations of the brain 10.3 VEGFA KDR IL6
44 radiation proctitis 10.3 VEGFA KDR FGF2
45 leukostasis 10.3 VEGFA KDR ICAM1
46 angiomatous meningioma 10.3 VEGFA KDR FGF2
47 parasitic protozoa infectious disease 10.3 KDR IL6 ICAM1
48 oral erosive lichen 10.3 IFNB1 IFNA1
49 squamous papillomatosis 10.3 IFNA2 IFNA1
50 vascular cancer 10.3 VEGFA KDR FGF2

Graphical network of the top 20 diseases related to Kaposi Sarcoma:



Diseases related to Kaposi Sarcoma

Symptoms & Phenotypes for Kaposi Sarcoma

Symptoms via clinical synopsis from OMIM:

57
Oncology:
kaposi sarcoma

Misc:
rarely familial

Skin:
red-purple nodules, plaques, and macules
limb edema


Clinical features from OMIM:

148000

Human phenotypes related to Kaposi Sarcoma:

59 32 (show all 29)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 59 32 occasional (7.5%) Occasional (29-5%) HP:0001945
2 fatigue 59 32 occasional (7.5%) Occasional (29-5%) HP:0012378
3 immunodeficiency 59 32 frequent (33%) Frequent (79-30%) HP:0002721
4 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
5 lymphedema 59 32 occasional (7.5%) Occasional (29-5%) HP:0001004
6 abnormality of the spleen 59 32 frequent (33%) Frequent (79-30%) HP:0001743
7 neoplasm of the skin 59 32 hallmark (90%) Very frequent (99-80%) HP:0008069
8 diarrhea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002014
9 skin rash 59 32 occasional (7.5%) Occasional (29-5%) HP:0000988
10 venous insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0005293
11 hypermelanotic macule 59 32 hallmark (90%) Very frequent (99-80%) HP:0001034
12 papule 59 32 frequent (33%) Frequent (79-30%) HP:0200034
13 abnormality of the gastrointestinal tract 59 32 frequent (33%) Frequent (79-30%) HP:0011024
14 abnormality of the liver 59 32 occasional (7.5%) Occasional (29-5%) HP:0001392
15 encephalopathy 59 32 frequent (33%) Frequent (79-30%) HP:0001298
16 abnormality of the lower limb 59 32 hallmark (90%) Very frequent (99-80%) HP:0002814
17 abnormal retinal morphology 59 32 frequent (33%) Frequent (79-30%) HP:0000479
18 skin nodule 59 32 frequent (33%) Frequent (79-30%) HP:0200036
19 skin plaque 59 32 occasional (7.5%) Occasional (29-5%) HP:0200035
20 hemangioma 59 32 frequent (33%) Frequent (79-30%) HP:0001028
21 lymphoproliferative disorder 59 32 frequent (33%) Frequent (79-30%) HP:0005523
22 generalized lymphadenopathy 59 32 frequent (33%) Frequent (79-30%) HP:0008940
23 susceptibility to herpesvirus 59 32 obligate (100%) Obligate (100%) HP:0005353
24 edema 32 HP:0000969
25 sarcoma 32 HP:0100242
26 macule 59 Very frequent (99-80%)
27 abnormality of lung morphology 59 Occasional (29-5%)
28 neoplasm by anatomical site 59 Occasional (29-5%)
29 abnormal lung morphology 32 occasional (7.5%) HP:0002088

UMLS symptoms related to Kaposi Sarcoma:


fever, pruritus, exanthema

MGI Mouse Phenotypes related to Kaposi Sarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 CDK6 FGF2 ICAM1 IFNB1 IL6 IL6ST
2 immune system MP:0005387 10.15 CCR8 CDK6 ICAM1 IFNB1 IL6 IL6ST
3 integument MP:0010771 9.92 ICAM1 IL6 IL6ST KDR PDGFB SLC7A11
4 liver/biliary system MP:0005370 9.8 CDK6 IL6 IL6ST KDR PDGFB TP53
5 muscle MP:0005369 9.76 CDK6 FGF2 ICAM1 IL6 KDR PDGFB
6 neoplasm MP:0002006 9.61 CDK6 FGF2 ICAM1 IFNB1 IL6 IL6ST
7 vision/eye MP:0005391 9.28 FGF2 ICAM1 IL6 IL6ST KDR PDGFB

Drugs & Therapeutics for Kaposi Sarcoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Taxol 18 49 PACLITAXEL Bristol-Myers Squibb August 1997

Drugs for Kaposi Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 203)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-22-7, 2068-78-2 5978
2
Bleomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
3
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 155213-67-5 392622
5
Efavirenz Approved, Investigational Phase 4,Phase 3,Not Applicable 154598-52-4 64139
6
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 134678-17-4 60825
7
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
8
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
9
Emtricitabine Approved, Investigational Phase 4,Phase 3,Not Applicable 143491-57-0 60877
10
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
11
Ganciclovir Approved, Investigational Phase 4,Phase 2,Not Applicable 82410-32-0 3454
12
Valganciclovir Approved, Investigational Phase 4,Phase 2,Not Applicable 175865-60-8 64147
13
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
14
Tenofovir Experimental, Investigational Phase 4,Phase 3,Not Applicable 147127-20-6 464205
15 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
16 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
17 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
18 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
19 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
20
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
21 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
22 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Not Applicable
23 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
25 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
26 Cytochrome P-450 CYP2C19 Inhibitors Phase 4,Phase 3,Not Applicable
27 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Not Applicable
28 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
29 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4,Phase 3
30 Ganciclovir triphosphate Phase 4,Phase 2,Not Applicable
31 Atazanavir Sulfate Phase 4,Phase 3
32
Meloxicam Approved, Vet_approved Phase 3 71125-38-7 54677470 5281106
33
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
34
Abacavir Approved, Investigational Phase 2, Phase 3 136470-78-5 65140 441300
35
Zidovudine Approved Phase 2, Phase 3,Phase 3,Phase 1 30516-87-1 35370
36
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
37
Daunorubicin Approved Phase 3,Phase 1 20830-81-3 30323
38
Aldesleukin Approved Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
39 tannic acid Approved Phase 3
40
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
41
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
42
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
43
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 1 1177-87-3
44 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
45 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
46 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
47 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
48 Antimitotic Agents Phase 3,Phase 2,Phase 1
49 Anti-Inflammatory Agents Phase 3,Phase 1,Phase 2,Not Applicable
50 Analgesics Phase 3,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 185)
# Name Status NCT ID Phase Drugs
1 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
2 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
3 Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease Withdrawn NCT00361933 Phase 4 Valganciclovir
4 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
5 A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
6 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
7 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir
8 Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma Completed NCT00003350 Phase 3 paclitaxel;pegylated liposomal doxorubicin hydrochloride
9 Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma Active, not recruiting NCT01352117 Phase 3 efavirenz/emtricitabine/tenofovir disoproxil fumarate;etoposide
10 Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
11 A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3 Doxorubicin hydrochloride (liposomal)
12 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3 Doxorubicin hydrochloride (liposomal)
13 Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients Completed NCT00002445 Phase 3 IM862
14 A Study of AZT in HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00000994 Phase 3 Zidovudine
15 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002105 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate
16 A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma. Completed NCT00002093 Phase 3 Daunorubicin (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
17 Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS Active, not recruiting NCT01435018 Phase 3 Coformulated EFV/FTC/TDF;Etoposide;Bleomycin and Vincristine (BV);Paclitaxel (PTX)
18 Mirasol Evaluation of Reduction in Infections Trial Not yet recruiting NCT03737669 Phase 3
19 PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV) Completed NCT01099579 Phase 3 Atazanavir powder;Ritonavir oral solution;Atazanavir capsules;Ritonavir capsules
20 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) Completed NCT00013611 Phase 3 Proleukin
21 Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone Completed NCT01924286 Phase 3 Prednisone;Placebo
22 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
23 Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) Recruiting NCT03092817 Phase 3 Dexamethasone
24 Antiviral Therapy in Treating Patients With Slowly Progressing HIV-Related Kaposi's Sarcoma Unknown status NCT00003419 Phase 2
25 Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer Unknown status NCT00622466 Phase 2 paclitaxel;sorafenib tosylate
26 Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma Recruiting NCT03077451 Phase 2 Nelfinavir Mesylate
27 Pomalidomide for Kaposi Sarcoma in People With or Without HIV Active, not recruiting NCT01495598 Phase 1, Phase 2 Pomalidomide
28 A Study of Selumetinib in Patients With Kaposi's Sarcoma Active, not recruiting NCT01752569 Phase 1, Phase 2 Selumetinib
29 Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's Sarcoma Completed NCT01067690 Phase 2 Indinavir in association with Vinblastina +/- Bleomicina
30 Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity Completed NCT01296815 Phase 2 Bevacizumab
31 PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma Terminated NCT00686842 Phase 1, Phase 2 VEGF inhibitor PTC299
32 Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS) Recruiting NCT03219671 Phase 2 Nivolumab;Ipilimumab
33 sEphB4-HSA in Treating Patients With Kaposi Sarcoma Recruiting NCT02799485 Phase 2
34 Valganciclovir Four Weeks Prior to cART Initiation Compared to Standard Therapy for Disseminated Kaposi Sarcoma Recruiting NCT03296553 Phase 2 Valganciclovir;Antiretroviral Combinations
35 Treatment of Classical Non-HIV-Related Kaposi's Sarcoma With the Antiviral Drug Indinavir Completed NCT00362310 Phase 2 indinavir
36 Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Completed NCT01057121 Phase 1, Phase 2 Lenalidomide
37 Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma Withdrawn NCT02229981 Phase 1, Phase 2 ABC294640
38 A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma Terminated NCT01412515 Phase 2 everolimus
39 Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00019188 Phase 1, Phase 2 interleukin-12
40 Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00064142 Phase 2 halofuginone hydrobromide
41 Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection Not yet recruiting NCT03601806 Phase 2 Pomalidomide
42 A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma Completed NCT02029430 Phase 2 aldoxorubicin
43 Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients Completed NCT00055237 Phase 2
44 Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma Withdrawn NCT00521092 Phase 2 sunitinib malate
45 A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma Terminated NCT00020683 Phase 2 incyclinide;incyclinide
46 Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma Withdrawn NCT02137564 Phase 2 gamma secretase inhibitor PF-03084014
47 Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT Completed NCT02201420 Phase 2 Tc 99m tilmanocept
48 Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma Completed NCT00295984 Phase 2 nicotine
49 Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00090987 Phase 2 imatinib mesylate
50 BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma Completed NCT00024024 Phase 1, Phase 2 rebimastat

Search NIH Clinical Center for Kaposi Sarcoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: sarcoma, kaposi

Genetic Tests for Kaposi Sarcoma

Genetic tests related to Kaposi Sarcoma:

# Genetic test Affiliating Genes
1 Kaposi's Sarcoma 29 IL6

Anatomical Context for Kaposi Sarcoma

MalaCards organs/tissues related to Kaposi Sarcoma:

41
Skin, Lymph Node, Lung, Endothelial, Prostate, Liver, T Cells

Publications for Kaposi Sarcoma

Articles related to Kaposi Sarcoma:

(show top 50) (show all 1488)
# Title Authors Year
1
KSHV viral load and Interleukin-6 in HIV-associated pediatric Kaposi sarcoma-Exploring the role of lytic activation in driving the unique clinical features seen in endemic regions. ( 30204240 )
2019
2
Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Associated Disease in the AIDS Patient: An Update. ( 30523621 )
2019
3
Kaposi Sarcoma in the Era of Rapamycin Remains a Therapeutic Challenge in Organ Transplant Recipients. ( 29527986 )
2018
4
Evolution of Kaposi sarcoma in the past 30A years in a tertiary hospital of the European Mediterranean basin. ( 29934954 )
2018
5
Case of classic Kaposi sarcoma of the penis successfully treated with radiotherapy. ( 29341256 )
2018
6
PD-1 blockade with nivolumab in endemic Kaposi sarcoma. ( 29324995 )
2018
7
Role of Radiotherapy in Mucosal Kaposi Sarcoma. ( 29383006 )
2018
8
Kaposi Sarcoma With Coexisting Intravascular Lymphoma. ( 29532696 )
2018
9
Membrane-Associated Kaposi Sarcoma-Associated Herpesvirus Glycoprotein B Promotes Cell Adhesion and Inhibits Migration of Cells via Upregulating IL-1I^ and TNF-I+. ( 29597230 )
2018
10
A case of recipient-derived pulmonary Kaposi sarcoma after bilateral lung transplantation. ( 29793656 )
2018
11
Kaposi Sarcoma of the Ear in HIV-Negative Patients. ( 29671213 )
2018
12
Kaposi sarcoma presenting shortly after primary infection by HIV and human herpesvirus-8. ( 29256918 )
2018
13
Kaposi sarcoma in an immunosuppressed young woman. ( 29398005 )
2018
14
Topical timolol for Kaposi sarcoma: An innovation. ( 29624656 )
2018
15
First application of hemi-body electron beam irradiation for Kaposi sarcoma at the lower extremities. ( 29552795 )
2018
16
Pseudo-Kaposi sarcoma: report of a case investigated by dermoscopy, reflectance confocal microscopy and optical coherence tomography. ( 29729117 )
2018
17
Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease. ( 29157621 )
2018
18
Recommendations for Counseling and Education of Service Members on Endemic African Cutaneous Kaposi Sarcoma: A Case Study. ( 29590438 )
2018
19
Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma. ( 29797733 )
2018
20
Eyelid Kaposi Sarcoma in an HIV-negative Patient. ( 29786002 )
2018
21
Kaposi Sarcoma After Allogeneic Hematopoietic Stem Cell Transplant: A Rare Complication. ( 29292681 )
2018
22
Age of Infection with Kaposi Sarcoma Associated Herpesvirus and Subsequent Antibody Values Among Children in Uganda. ( 29369149 )
2018
23
Relationship between Anaemia, Malaria Co-infection and Kaposi Sarcoma-associated Herpesvirus (KSHV) Seropositivity in a Population-based Study in Rural Uganda. ( 29741631 )
2018
24
Exploring the Role of IL-32 in HIV-Related Kaposi Sarcoma. ( 29037857 )
2018
25
Epidemiology of Kaposi sarcoma: review and description of the nonepidemic variant. ( 29888407 )
2018
26
Kaposi sarcoma of the upper eyelid: a rare occurrence. ( 29888854 )
2018
27
Disseminated Kaposi sarcoma with epithelioid morphology in an HIV/AIDS patient: A previously unreported variant. ( 29660143 )
2018
28
Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away. Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy. ( 29282751 )
2018
29
The Kaposi Sarcoma Herpesvirus non-structural membrane protein pK15 recruits the class II PI3K Phosphatidylinositol 4-phosphate 3-kinase C2 alpha to activate productive viral replication. ( 29950425 )
2018
30
As-Needed versus Immediate Etoposide Chemotherapy in Combination with Antiretroviral Therapy for Mild or Moderate AIDS-associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. ( 29365083 )
2018
31
Rubbery purple and red lesions in the GI tract: A Case of GI tract Kaposi Sarcoma. ( 29306041 )
2018
32
Kaposi Sarcoma and Cutaneous Angiosarcoma: Guidelines for Diagnosis and Treatment. ( 30262126 )
2018
33
Plastic Bronchitis in an AIDS Patient with Pulmonary Kaposi Sarcoma. ( 30363701 )
2018
34
Newly diagnosed AIDS with neurosyphilis, Kaposi sarcoma, pancytopenia, oropharyngeal candidiasis, and pseudomonal pneumonia: We shouldn't be seeing this anymore. ( 30101071 )
2018
35
Acroangiodermatitis of Mali (Pseudo-Kaposi Sarcoma) Associated with Chronic Venous Insufficiency and Obesity: A Case Report. ( 30457563 )
2018
36
Reversible rituximab-induced rectal Kaposi's sarcoma misdiagnosed as ulcerative colitis in a patient with HIV-negative follicular lymphoma. ( 29992013 )
2018
37
Iatrogenic Kaposi's Sarcoma in an HIV-Negative Young Male With Crohn's Disease and IgA Nephropathy: A Case Report and Brief Review of the Literature. ( 29169276 )
2018
38
Endemic Kaposi sarcoma in HIV-negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV-related disease. ( 30455728 )
2018
39
Successful treatment of primary donor-derived human herpesvirus-8 infection and hepatic Kaposi Sarcoma in an adult liver transplant recipient. ( 30014622 )
2018
40
Triple therapy of vincristine, bleomycin and etoposide for children with Kaposi sarcoma: Results of a study in Malawian children. ( 28988435 )
2018
41
Evidence for Kaposi Sarcoma Originating from Mesenchymal Stem Cell through KSHV-induced Mesenchymal-to-Endothelial Transition. ( 29066510 )
2018
42
Kaposi Sarcoma-Associated Herpesvirus in a Rural Ugandan Cohort, 1992-2008. ( 29099933 )
2018
43
Head and Neck Kaposi Sarcoma: Clinicopathological Analysis of 11 Cases. ( 29508130 )
2018
44
Pediatric Kaposi sarcoma in context of the HIV epidemic in sub-Saharan Africa: current perspectives. ( 29722363 )
2018
45
Impact of Protease Inhibitors on HIV-Associated Kaposi Sarcoma Incidence: A Systematic Review. ( 29985803 )
2018
46
Risk of Kaposi sarcoma after solid organ transplantation in the United States. ( 29987894 )
2018
47
Response to Checkpoint Inhibitor Therapy in Advanced Classic Kaposi Sarcoma: A Case Report and Immunogenomic Study. ( 30006421 )
2018
48
Genome-Wide Sequence Analysis of Kaposi Sarcoma-Associated Herpesvirus Shows Diversification Driven by Recombination. ( 30010810 )
2018
49
The hunt for the earliest cases of AIDS-related Kaposi sarcoma: a retrospective outbreak investigation. ( 30011064 )
2018
50
Trends and Histopathological Patterns of Kaposi Sarcoma at The University of Benin Teaching Hospital, Benin City, Nigeria. ( 30038734 )
2018

Variations for Kaposi Sarcoma

ClinVar genetic disease variations for Kaposi Sarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 IL6 IL6, -174G-C single nucleotide variant risk factor

Cosmic variations for Kaposi Sarcoma:

9 (show all 29)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM575 NRAS soft tissue,skin,sarcoma,NS c.38G>C p.G13A 1:114716123-114716123 69
2 COSM6979022 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 68
3 COSM389868 RAC1 soft tissue,lung,sarcoma,NS c.476C>T p.A159V 7:6402343-6402343 68
4 COSM6979014 PTPRD soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 68
5 COSM6959031 PTCH1 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 68
6 COSM6979006 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 68
7 COSM6979021 PAK5 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 68
8 COSM520 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 68
9 COSM516 KRAS soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 68
10 COSM6979011 HGF soft tissue,lung,sarcoma,NS c.1711G>T p.V571L 7:81706333-81706333 68
11 COSM6959034 GPS2 soft tissue,lung,sarcoma,NS c.454C>T p.Q152* 17:7313932-7313932 68
12 COSM6979008 FOXP1 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 68
13 COSM6959030 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 68
14 COSM6979007 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 68
15 COSM6979005 soft tissue,lung,sarcoma,NS c.2738G>A p.R913H 3:52589201-52589201 68
16 COSM6979015 soft tissue,lung,sarcoma,NS c.2939C>T p.A980V 9:8404587-8404587 68
17 COSM6979012 soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 68
18 COSM6979020 soft tissue,lung,sarcoma,NS c.1831+1G>T p.? 19:45353082-45353082 68
19 COSM1140136 soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 68
20 COSM6979017 soft tissue,lung,sarcoma,NS c.2573C>T p.A858V 9:8404587-8404587 68
21 COSM6979010 soft tissue,lung,sarcoma,NS c.1036G>T p.V346L 3:179203766-179203766 68
22 COSM6979009 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 68
23 COSM1154840 soft tissue,lung,sarcoma,NS c.533C>T p.A178V 7:6402343-6402343 68
24 COSM6959033 soft tissue,lung,sarcoma,NS c.2918T>G p.F973C 9:95458260-95458260 68
25 COSM6979016 soft tissue,lung,sarcoma,NS c.2930C>T p.A977V 9:8404587-8404587 68
26 COSM6979013 soft tissue,lung,sarcoma,NS c.2942C>T p.A981V 9:8404587-8404587 68
27 COSM6959032 soft tissue,lung,sarcoma,NS c.2918T>G p.F973C 9:95458260-95458260 68
28 COSM521 KRAS biliary tract,gallbladder,other,hyperplasia c.35G>A p.G12D 12:25245350-25245350 6
29 COSM517 KRAS biliary tract,gallbladder,other,hyperplasia c.34G>A p.G12S 12:25245351-25245351 6

Expression for Kaposi Sarcoma

Search GEO for disease gene expression data for Kaposi Sarcoma.

Pathways for Kaposi Sarcoma

Pathways related to Kaposi Sarcoma according to KEGG:

37
# Name Kegg Source Accession
1 Kaposi sarcoma-associated herpesvirus infection hsa05167
2 Viral carcinogenesis hsa05203

Pathways related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 ADA2 CXCL1 FGF2 FGF4 ICAM1 IFNA1
2
Show member pathways
13.9 FGF2 FGF4 IFNA1 IFNA2 IFNB1 IL6
3
Show member pathways
13.89 CCR8 CDK6 CXCL1 FGF2 FGF4 IL6
4
Show member pathways
13.7 CCR8 CXCL1 IFNA1 IFNA2 IFNB1 IL6
5
Show member pathways
13.51 FGF2 FGF4 ICAM1 IFNA1 IFNA2 IFNB1
6
Show member pathways
13.42 CCR8 CXCL1 FGF2 FGF4 IL6 KDR
7
Show member pathways
13.33 IFNA1 IFNA2 IFNB1 IRF7 PDGFB SLC7A11
8
Show member pathways
13.32 CCR8 CXCL1 FGF2 FGF4 IL6 KDR
9
Show member pathways
13.08 FGF2 FGF4 IL6 KDR PDGFB TP53
10
Show member pathways
13.08 CXCL1 FGF2 FGF4 ICAM1 IFNA1 IFNA2
11
Show member pathways
13.02 CXCL1 IFNA1 IFNA2 IFNB1 IL6 IRF7
12
Show member pathways
12.84 CDK6 FGF2 FGF4 IFNA1 IFNA2 IFNB1
13 12.79 CDK6 FGF2 FGF4 IFNA1 IFNA2 IL6
14
Show member pathways
12.78 IFNA1 IFNA2 IFNB1 IL6 IRF7
15 12.78 FGF2 FGF4 KDR PDGFB TP53 VEGFA
16
Show member pathways
12.78 CDK6 FGF2 FGF4 IL6 KDR PDGFB
17
Show member pathways
12.75 FGF2 FGF4 KDR PDGFB VEGFA
18
Show member pathways
12.75 ALYREF CDK6 ICAM1 IFNA1 IFNA2 IFNB1
19
Show member pathways
12.71 FGF2 FGF4 IL6 KDR PDGFB
20
Show member pathways
12.6 CXCL1 FGF2 IL6 PDGFB TP53
21
Show member pathways
12.56 ICAM1 IFNA1 IFNA2 IFNB1 IRF7
22 12.44 ICAM1 IL6 PDGFB TP53
23
Show member pathways
12.44 IFNA1 IFNA2 IFNB1 IL6 IL6ST PDGFB
24
Show member pathways
12.41 FGF2 FGF4 KDR VEGFA
25
Show member pathways
12.41 FGF2 FGF4 IL6 KDR PDGFB
26
Show member pathways
12.35 CCR8 CDK6 CXCL1 FGF2 ICAM1 IFNA1
27
Show member pathways
12.32 IFNA1 IFNA2 IFNB1 IL6
28 12.32 CCR8 CDK6 IL6ST IRF7 TP53
29 12.3 FGF2 KDR TP53 VEGFA
30 12.24 IFNA1 IFNA2 IFNB1 IL6
31 12.23 CDK6 ICAM1 IFNA1 IFNA2 IFNB1 IL6
32 12.2 IFNA1 IFNA2 IFNB1 IRF7 TP53
33 12.13 ICAM1 KDR PDGFB TP53 VEGFA
34
Show member pathways
12.1 FGF2 FGF4 ICAM1 IL6 KDR PDGFB
35 12.1 FGF2 FGF4 IL6 KDR PDGFB VEGFA
36 12.09 IFNA1 IFNA2 IFNB1 IRF7 TP53
37 12.03 CXCL1 ICAM1 IL6 TP53
38 12 FGF2 ICAM1 IL6 TP53 VEGFA
39 11.98 CXCL1 ICAM1 IFNB1 IL6
40 11.96 CXCL1 IFNB1 IL6 IL6ST IRF7 TP53
41 11.91 IFNA1 IFNA2 IFNB1 IL6 IL6ST
42 11.9 ICAM1 IL6 VEGFA
43
Show member pathways
11.9 CXCL1 ICAM1 IL6 IL6ST
44 11.88 CXCL1 ICAM1 IL6 VEGFA
45
Show member pathways
11.86 FGF2 FGF4 IFNA1 IFNA2 IFNB1 IL6
46 11.82 ICAM1 IL6 TP53
47 11.82 FGF2 FGF4 PDGFB VEGFA
48 11.77 IFNA2 IFNB1 IL6
49 11.68 FGF2 IL6 PDGFB
50
Show member pathways
11.68 ICAM1 IL6 VEGFA

GO Terms for Kaposi Sarcoma

Cellular components related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 ADA2 CXCL1 FGF2 ICAM1 IFNA1 IFNA2
2 extracellular region GO:0005576 9.4 ADA2 CXCL1 FGF2 FGF4 IFNA1 IFNA2
3 interleukin-6 receptor complex GO:0005896 9.16 IL6 IL6ST

Biological processes related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.98 IFNA2 KDR PDGFB VEGFA
2 extracellular matrix organization GO:0030198 9.97 FGF2 ICAM1 KDR PDGFB
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 FGF2 FGF4 ICAM1 KDR PDGFB
4 positive regulation of cell proliferation GO:0008284 9.95 FGF2 FGF4 IL6 IL6ST KDR PDGFB
5 peptidyl-tyrosine phosphorylation GO:0018108 9.94 FGF2 FGF4 KDR PDGFB
6 defense response GO:0006952 9.91 CXCL1 IFNA1 IFNA2 IFNB1
7 defense response to virus GO:0051607 9.89 IFNA1 IFNA2 IFNB1 IL6 IRF7
8 B cell differentiation GO:0030183 9.85 IFNA1 IFNA2 IFNB1
9 positive regulation of MAP kinase activity GO:0043406 9.84 FGF2 PDGFB VEGFA
10 positive chemotaxis GO:0050918 9.8 FGF2 PDGFB VEGFA
11 positive regulation of endothelial cell proliferation GO:0001938 9.78 FGF2 KDR PDGFB VEGFA
12 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.77 FGF2 KDR VEGFA
13 B cell proliferation GO:0042100 9.76 IFNA1 IFNA2 IFNB1
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 IFNA2 IL6 IL6ST VEGFA
15 response to exogenous dsRNA GO:0043330 9.75 IFNA1 IFNA2 IFNB1
16 type I interferon signaling pathway GO:0060337 9.73 IFNA1 IFNA2 IFNB1 IRF7
17 T cell activation involved in immune response GO:0002286 9.72 IFNA1 IFNA2 IFNB1
18 cell migration involved in sprouting angiogenesis GO:0002042 9.71 FGF2 KDR VEGFA
19 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.7 IFNA1 IFNA2 IFNB1
20 interleukin-6-mediated signaling pathway GO:0070102 9.69 IL6 IL6ST
21 natural killer cell activation involved in immune response GO:0002323 9.69 IFNA1 IFNA2 IFNB1
22 positive regulation of DNA biosynthetic process GO:2000573 9.68 FGF2 PDGFB
23 positive regulation of acute inflammatory response GO:0002675 9.68 IL6 IL6ST
24 positive regulation of positive chemotaxis GO:0050927 9.68 KDR VEGFA
25 humoral immune response GO:0006959 9.67 IFNA1 IFNA2 IFNB1 IL6
26 paracrine signaling GO:0038001 9.65 FGF2 PDGFB
27 negative regulation of T cell differentiation GO:0045581 9.65 IFNA2 IFNB1
28 regulation of signaling receptor activity GO:0010469 9.65 ADA2 CXCL1 FGF2 FGF4 IFNA1 IFNA2
29 chondroblast differentiation GO:0060591 9.64 FGF2 FGF4
30 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.63 KDR VEGFA
31 negative regulation of T-helper 2 cell cytokine production GO:2000552 9.62 IFNA2 IFNB1
32 positive regulation of blood vessel endothelial cell migration GO:0043536 9.62 FGF2 KDR PDGFB VEGFA
33 regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000544 9.59 FGF2 FGF4
34 positive regulation of cell division GO:0051781 9.56 FGF2 FGF4 PDGFB VEGFA
35 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.55 ICAM1 IL6 PDGFB TP53 VEGFA
36 cytokine-mediated signaling pathway GO:0019221 9.32 CXCL1 FGF2 ICAM1 IFNA1 IFNA2 IFNB1
37 positive regulation of transcription by RNA polymerase II GO:0045944 10.2 FGF2 FGF4 IFNB1 IL6 IRF7 TP53
38 multicellular organism development GO:0007275 10.2 ADA2 FGF2 FGF4 KDR PDGFB TP53
39 positive regulation of transcription, DNA-templated GO:0045893 10.1 FGF2 IFNA2 IL6 IRF7 PDGFB TP53
40 negative regulation of apoptotic process GO:0043066 10.08 FGF4 IL6 IL6ST KDR TP53 VEGFA
41 positive regulation of gene expression GO:0010628 10.06 FGF4 IL6 PDGFB TP53 VEGFA
42 viral process GO:0016032 10.03 ALYREF ICAM1 IL6ST IRF7 KDR TP53

Molecular functions related to Kaposi Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.67 ADA2 FGF2 FGF4 VEGFA
2 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.61 FGF2 FGF4 PDGFB
3 chemoattractant activity GO:0042056 9.5 FGF2 PDGFB VEGFA
4 cytokine activity GO:0005125 9.5 CXCL1 FGF2 IFNA1 IFNA2 IFNB1 IL6
5 platelet-derived growth factor receptor binding GO:0005161 9.46 PDGFB VEGFA
6 cytokine receptor binding GO:0005126 9.43 IFNA1 IFNA2 IFNB1
7 interleukin-6 receptor binding GO:0005138 9.4 IL6 IL6ST
8 type I interferon receptor binding GO:0005132 9.33 IFNA1 IFNA2 IFNB1
9 growth factor activity GO:0008083 9.17 ADA2 CXCL1 FGF2 FGF4 IL6 PDGFB

Sources for Kaposi Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....